We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.

Delisted

BHVN was delisted on the 3rd of October, 2022.

215 hedge funds and large institutions have $3.9B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 85 increasing their positions, 78 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more call options, than puts

Call options by funds: $95M | Put options by funds: $45.4M

9% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 78

5% less funds holding

Funds holding: 226215 (-11)

10% less capital invested

Capital invested by funds: $4.34B → $3.9B (-$442M)

19% less funds holding in top 10

Funds holding in top 10: 1613 (-3)

33% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 33

Holders
215
Holders Change
-11
Holders Change %
-4.87%
% of All Funds
4.34%
Holding in Top 10
13
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-18.75%
% of All Funds
0.26%
New
22
Increased
85
Reduced
78
Closed
33
Calls
$95M
Puts
$45.4M
Net Calls
+$49.5M
Net Calls Change
-$72.8M
Name Holding Trade Value Shares
Change
Change in
Stake
CCI
26
Columbus Circle Investors
$39.1M +$6.46M +98,642 +20%
TCM
27
Tang Capital Management
California
$38.9M -$25M -381,370 -39%
Northern Trust
28
Northern Trust
Illinois
$37.1M -$1.02M -15,497 -3%
AIP
29
ARS Investment Partners
New York
$36.4M -$2.99M -45,668 -8%
Deutsche Bank
30
Deutsche Bank
Germany
$34.3M -$5.44M -82,957 -14%
CAM
31
Cormorant Asset Management
Massachusetts
$32.5M -$6.55M -100,000 -17%
Thrivent Financial for Lutherans
32
Thrivent Financial for Lutherans
Minnesota
$32.4M +$21.8M +332,014 +200%
Norges Bank
33
Norges Bank
Norway
$31.7M -$1.65M -25,237 -5%
CTA
34
Carillon Tower Advisers
Florida
$31.6M +$1.37M +20,878 +4%
Goldman Sachs
35
Goldman Sachs
New York
$30.3M +$2.68M +40,932 +10%
Adage Capital Partners
36
Adage Capital Partners
Massachusetts
$29.3M +$16.4M +250,000 +125%
GPP
37
Great Point Partners
Connecticut
$28.3M -$26.6M -405,900 -48%
EAM
38
EULAV Asset Management
Florida
$26.3M +$880K +13,427 +3%
SC
39
Samlyn Capital
New York
$25.5M -$9.41M -143,574 -27%
ClearBridge Investments
40
ClearBridge Investments
New York
$24M +$5.89M +89,811 +32%
Charles Schwab
41
Charles Schwab
California
$22.2M +$1.62M +24,684 +8%
EP
42
Eversept Partners
New York
$20.9M -$8.3M -126,683 -28%
RPAM
43
Rhenman & Partners Asset Management
Sweden
$20.2M +$6.55M +100,000 +48%
Two Sigma Investments
44
Two Sigma Investments
New York
$17.9M +$12.4M +189,121 +218%
N
45
Nuveen
North Carolina
$17.9M -$1.67M -25,496 -8%
Handelsbanken Fonder
46
Handelsbanken Fonder
Sweden
$17.5M +$1.65M +25,200 +10%
AAP
47
Ardsley Advisory Partners
Connecticut
$16.7M -$2.94M -44,900 -15%
NIP
48
Nicholas Investment Partners
California
$16.4M +$12.6M +192,988 +327%
CWG
49
C WorldWide Group
Denmark
$16.4M +$3.28M +50,000 +25%
PAMU
50
Pictet Asset Management (UK)
United Kingdom
$13.4M +$45.5K +695 +0.3%

BHVN Hedge Fund Activity: Q3 2020 in Review

215 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2020, worth a combined $3.9B — down 10% from $4.34B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of BHVN and 22 opened new positions — a net loss of 11 holders — while 78 trimmed existing stakes and 85 added.

The largest buyer was Capital World Investors, adding an estimated $72.8M. The largest seller was Vanguard Group, cutting an estimated $29.8M.

  • 215 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2020, down from 226 in Q2 2020.
  • Funds reported $3.9B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2020, down 10% quarter-over-quarter.
  • 22 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2020 and 33 closed out, a net change of -11 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2020 was Capital World Investors, an estimated $72.8M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q3 2020 was Vanguard Group, an estimated $29.8M sold.

Based on aggregated 13F filings for Q3 2020.